Simponi positive in Phase III for ulcerative colitis
This article was originally published in Scrip
Executive Summary
New Phase III data show that the fully human anti-tumour necrosis factor (TNF)-alpha therapy Simponi (golimumab) induced a clinical response in a majority of patients with moderately to severely active ulcerative colitis (UC) who had previously failed or were intolerant to conventional agents but were naïve to anti-TNF therapies.